Apeiron RIA LLC Buys 19,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Apeiron RIA LLC grew its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 262,542 shares of the biotechnology company’s stock after buying an additional 19,000 shares during the quarter. Apeiron RIA LLC owned 0.17% of Heron Therapeutics worth $402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the company. Capital Planning Advisors LLC lifted its stake in shares of Heron Therapeutics by 41.0% in the 4th quarter. Capital Planning Advisors LLC now owns 106,565 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 31,003 shares during the period. Arkadios Wealth Advisors bought a new position in Heron Therapeutics in the fourth quarter worth approximately $76,000. Congress Park Capital LLC raised its position in Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock worth $3,757,000 after acquiring an additional 477,417 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Heron Therapeutics by 295.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 154,487 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Heron Therapeutics by 456.5% during the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 84,205 shares during the period. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $1.76 on Friday. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The company’s fifty day moving average price is $1.49 and its 200-day moving average price is $1.92. The company has a market capitalization of $267.69 million, a price-to-earnings ratio of -9.78 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same quarter in the previous year, the company posted ($0.17) EPS. Equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HRTX has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Wednesday, December 4th. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.